Drug intelligence / Profile preview

Midazolam + Ondansetron

Development stage
Unknown
Lead developer
ImprimisRx
Modality
Small Molecules
Administration
Intravenous
01

Overview

The combination of midazolam and ondansetron is used primarily for preventing postoperative nausea and vomiting (PONV), particularly in surgical settings. Studies have shown that this combination is more effective than using either drug alone. Midazolam is a benzodiazepine with sedative, anxiolytic, and amnestic properties, while ondansetron is a serotonin 5-HT3 receptor antagonist that works by blocking serotonin action, which can cause nausea and vomiting. ## Pharmacological Properties Midazolam provides sedation and anxiolysis, making it useful in surgical settings. It's commonly administered before or during diagnostic or therapeutic procedures. Ondansetron specifically targets the mechanisms that cause nausea and vomiting, making it effective for preventing PONV. Research has demonstrated that the combination of midazolam (0.75 mg/kg) with ondansetron (4 mg) is more effective than using either medication alone in preventing PONV after middle ear surgery[1]. Another study showed that midazolam added to patient-controlled analgesia (PCA) using fentanyl was more effective than ondansetron in preventing PONV without adverse effects[4]. ## Clinical Applications The combination is primarily used in: - Prevention of postoperative nausea and vomiting - Sedation before or during surgical procedures - Management of nausea and vomiting in various clinical settings When used together, these medications have shown a synergistic effect in reducing PONV incidence rates, particularly in the immediate postoperative period[4]. ## Safety Considerations There are numerous drug interactions to be aware of when using this combination. According to the search results, there are 806 drugs known to interact with ketamine/midazolam/ondansetron, with 327 major interactions, 450 moderate interactions, and 29 minor interactions[2]. Additionally, there are 16 disease interactions and 4 alcohol/food interactions to consider[2][5]. The combination appears to be physicochemically stable and safe when properly administered[4]. However, careful monitoring is essential due to the potential for sedative effects and other adverse reactions.

02

Targets

GABRR (GABA-A receptor subunit rho)HTR3A (5-hydroxytryptamine receptor 3A)

Beyond the preview

Go deeper on Midazolam + Ondansetron.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Midazolam + Ondansetron.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call